Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...

Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...